Association Between Heparin Dose, Body Mass Index, and Stroke Risk in Patients Undergoing TAVR

Journal of Clinical Medicine 2026 Open access

Read full text
Authors: Ziad Arow, Juri Iwata, Akiko Masumoto, Arthur Clement, Laurent Lepage, Laurent Bonfils, Rawia Hussein-Aro, Abid Assali, Nicolas Dumonteil, Didier Tchétché, Chiara De Biase
DOI: 10.3390/jcm15031201
Cited by: 0
References: 17

Abstract

Background: Unfractionated heparin (UFH) is routinely administered during transcatheter aortic valve replacement (TAVR) to prevent thromboembolic complications. However, there are no clear evidence-based guidelines defining optimal heparin dosing or target activated clotting time (ACT) values. This study aimed to evaluate the association between intraprocedural UFH dosing, ACT values, and peri-procedural stroke risk in the overall population of patients undergoing TAVR, with a prespecified stratified analysis according to body mass index (BMI ≥ 30 vs.

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Atrial Fibrillation Management and Outcomes Infective Endocarditis Diagnosis and Management

Publication details

Journal / source
Journal of Clinical Medicine
Volume
15
Issue
3
Pages
1201–1201
Publication date
3 February 2026
Language
EN